Dr. Bekaii-Saab on Expanding Landscape in CRC

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the expanding treatment landscape of colorectal cancer (CRC).

The armamentarium in CRC is expanding; moreover, agents across multiple lines of therapy are becoming available for patients and, overall, improving their survival, Bekaii-Saab explains. It is very important to understand sequencing of therapies, he adds. This is a major question currently among the CRC community.

In the second-line setting, there are 2 agents available: regorafenib (Stivarga) and TAS-102. The optimal sequence of these agents in the second-line setting is still unknown, he adds.